Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain

Phase 3

Completed

• Conditions: Pain, Postoperative

• Registration Number: NCT00143169
• Lead Sponsor: Pfizer

Brief Summary

To validate the morphine-sparing effect and safety of parecoxib administered intravenously for the treatment of Chinese subjects with postoperative pain following gynecological or orthopedic surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study Completion: 2005-06
• Study First Submitted: 2005-08-31
• Study First Submitted QC: 2005-08-31
• Study First Posted: 2005-09-02
• Status Verified: 2005-11
• Last Update Submitted: 2008-04-14
• Last Update Posted: 2008-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• Undergo gynecological or orthopedic surgery under epidural anesthesia

Exclusion Criteria

• A previous history of intolerance or hypersensitivity to any NSAID, cyclooxygenase-2 selective inhibitors, sulphonamides, or any of the excipients of parecoxib.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To validate the morphine-sparing effect of parecoxib administered intravenously for the treatment of Chinese subjects with postoperative pain following gynecological or orthopedic surgery.

Secondary Outcome Measures

Name	Time	Method
To validate safety of parecoxib administered intravenously for the treatment of Chinese subjects with postoperative pain following gynecological or orthopedic surgery.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇨🇳 Shanghai, China